Telos Capital Management Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,102 shares of the company’s stock after purchasing an additional 160 shares during the period. Telos Capital Management Inc.’s holdings in Eli Lilly and were worth $1,700,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in the stock. AFT Forsyth & Company Inc. lifted its holdings in Eli Lilly and by 0.8% during the 4th quarter. AFT Forsyth & Company Inc. now owns 6,695 shares of the company’s stock worth $1,130,000 after purchasing an additional 50 shares during the last quarter. Horizon Investment Services LLC raised its holdings in Eli Lilly and by 2.7% in the 4th quarter. Horizon Investment Services LLC now owns 1,904 shares of the company’s stock valued at $321,000 after acquiring an additional 50 shares in the last quarter. CRA Financial Services LLC raised its holdings in Eli Lilly and by 1.2% in the 4th quarter. CRA Financial Services LLC now owns 4,316 shares of the company’s stock valued at $729,000 after acquiring an additional 51 shares in the last quarter. Meridian Wealth Management LLC raised its holdings in Eli Lilly and by 2.9% in the 4th quarter. Meridian Wealth Management LLC now owns 1,887 shares of the company’s stock valued at $318,000 after acquiring an additional 53 shares in the last quarter. Finally, Park Avenue Securities LLC raised its holdings in Eli Lilly and by 1.1% in the 4th quarter. Park Avenue Securities LLC now owns 5,091 shares of the company’s stock valued at $860,000 after acquiring an additional 55 shares in the last quarter. 75.59% of the stock is owned by institutional investors and hedge funds.
LLY has been the subject of several analyst reports. Cowen lifted their price objective on Eli Lilly and from $195.00 to $235.00 and gave the company an “outperform” rating in a report on Friday, February 12th. Truist boosted their price target on Eli Lilly and from $200.00 to $215.00 in a report on Monday, February 1st. Barclays lowered their price target on Eli Lilly and from $232.00 to $227.00 and set an “overweight” rating for the company in a report on Wednesday, April 28th. Truist Securities boosted their price target on Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, March 22nd. Finally, Mizuho lowered their price target on Eli Lilly and from $228.00 to $216.00 and set a “buy” rating for the company in a report on Wednesday, April 28th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Buy” and an average target price of $200.75.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Monday, April 26th. The company reported $1.87 EPS for the quarter, missing analysts’ consensus estimates of $2.12 by ($0.25). Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The company had revenue of $6.81 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter last year, the firm posted $1.75 EPS. The company’s quarterly revenue was up 16.1% on a year-over-year basis. As a group, analysts forecast that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 10th. Shareholders of record on Friday, May 14th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 1.83%. Eli Lilly and’s dividend payout ratio (DPR) is presently 56.29%.
In other news, major shareholder Lilly Endowment Inc sold 125,284 shares of the business’s stock in a transaction dated Monday, March 8th. The stock was sold at an average price of $209.69, for a total value of $26,270,801.96. Following the transaction, the insider now directly owns 110,422,933 shares of the company’s stock, valued at approximately $23,154,584,820.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jackson P. Tai acquired 1,366 shares of the company’s stock in a transaction dated Friday, April 30th. The stock was acquired at an average cost of $182.84 per share, for a total transaction of $249,759.44. Following the completion of the purchase, the director now directly owns 60,649 shares in the company, valued at $11,089,063.16. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Further Reading: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.